WO2003015703A3 - Compositions et procedes relatifs a de nouveaux composes de benzodiazepine et leurs cibles - Google Patents

Compositions et procedes relatifs a de nouveaux composes de benzodiazepine et leurs cibles Download PDF

Info

Publication number
WO2003015703A3
WO2003015703A3 PCT/US2002/026171 US0226171W WO03015703A3 WO 2003015703 A3 WO2003015703 A3 WO 2003015703A3 US 0226171 W US0226171 W US 0226171W WO 03015703 A3 WO03015703 A3 WO 03015703A3
Authority
WO
WIPO (PCT)
Prior art keywords
targets
compositions
methods relating
benzodiazepine compounds
novel benzodiazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/026171
Other languages
English (en)
Other versions
WO2003015703A2 (fr
Inventor
Gary D Glick
Anthony W Opipari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/217,878 external-priority patent/US20030119029A1/en
Priority to EP02794914A priority Critical patent/EP1423122A4/fr
Priority to NZ531117A priority patent/NZ531117A/xx
Priority to JP2003520664A priority patent/JP2005502652A/ja
Priority to AU2002332560A priority patent/AU2002332560B2/en
Priority to MXPA04001421A priority patent/MXPA04001421A/es
Application filed by University of Michigan System, University of Michigan Ann Arbor filed Critical University of Michigan System
Priority to CA002457405A priority patent/CA2457405A1/fr
Publication of WO2003015703A2 publication Critical patent/WO2003015703A2/fr
Publication of WO2003015703A3 publication Critical patent/WO2003015703A3/fr
Anticipated expiration legal-status Critical
Priority to NO20041058A priority patent/NO20041058L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention porte sur de nouveaux composés chimiques, sur leurs méthodes de recherche et leur utilisation thérapeutique. L'invention porte notamment sur des dérivés de benzodiazépine et sur leurs procédés d'utilisation comme agents thérapeutiques afin de traiter plusieurs états associés à une mauvaise régulation des processus de la mort cellulaire programmée, l'auto-immunité, l'inflammation, l'hyperprolifération et autre.
PCT/US2002/026171 2001-08-15 2002-08-15 Compositions et procedes relatifs a de nouveaux composes de benzodiazepine et leurs cibles Ceased WO2003015703A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002457405A CA2457405A1 (fr) 2001-08-15 2002-08-15 Compositions et methodes relatives a des benzodiazepines
NZ531117A NZ531117A (en) 2001-08-15 2002-08-15 Compositions and methods relating to novel benzodiazepine compounds and targets thereof
JP2003520664A JP2005502652A (ja) 2001-08-15 2002-08-15 新規ベンゾジアゼピン化合物に関連した組成物および方法、ならびにそれらの標的
AU2002332560A AU2002332560B2 (en) 2001-08-15 2002-08-15 Compositions and methods relating to novel benzodiazepine compounds and targets thereof
MXPA04001421A MXPA04001421A (es) 2001-08-15 2002-08-15 Composiciones y metodos que se relacionan con compuestos novedosos de benzodiazepina y sus destinos.
EP02794914A EP1423122A4 (fr) 2001-08-15 2002-08-15 Compositions et procedes relatifs a de nouveaux composes de benzodiazepine et leurs cibles
NO20041058A NO20041058L (no) 2001-08-15 2004-03-12 Preparater og fremgangsmater relatert til nye benzodiazepinforbindelser og mal derav

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US31256001P 2001-08-15 2001-08-15
US60/312,560 2001-08-15
US31368901P 2001-08-20 2001-08-20
US60/313,689 2001-08-20
US39667002P 2002-07-18 2002-07-18
US60/396,670 2002-07-18
US10/217,878 2002-08-13
US10/217,878 US20030119029A1 (en) 1999-04-30 2002-08-13 Compositions and methods relating to novel benzodiazepine compounds and targets thereof

Publications (2)

Publication Number Publication Date
WO2003015703A2 WO2003015703A2 (fr) 2003-02-27
WO2003015703A3 true WO2003015703A3 (fr) 2003-11-13

Family

ID=27499087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/026171 Ceased WO2003015703A2 (fr) 2001-08-15 2002-08-15 Compositions et procedes relatifs a de nouveaux composes de benzodiazepine et leurs cibles

Country Status (8)

Country Link
EP (1) EP1423122A4 (fr)
JP (1) JP2005502652A (fr)
AU (1) AU2002332560B2 (fr)
CA (1) CA2457405A1 (fr)
MX (1) MXPA04001421A (fr)
NO (1) NO20041058L (fr)
NZ (1) NZ531117A (fr)
WO (1) WO2003015703A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572788B2 (en) 1999-04-30 2009-08-11 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7994313B2 (en) 2005-06-01 2011-08-09 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
JP5127096B2 (ja) 1999-04-30 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用
US7276348B2 (en) 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
US20060025388A1 (en) * 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
CA2524394C (fr) * 2003-05-01 2011-07-12 The Regents Of The University Of Michigan Nouvelles benzodiazepines, compositions de celles-ci et leurs utilisations
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
JP2008528448A (ja) 2005-01-03 2008-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 新規化合物に関連する組成物および方法、ならびにその標的
BRPI0520554A2 (pt) 2005-09-19 2009-06-13 Arrow Therapeutics Ltd uso de uma benzodiazepina ou um sal farmaceuticamente aceitável do mesmo, método para tratar ou prevenir uma infecção por hcv em um paciente, derivado de benzodiazepina ou um sal famaceuticamente aceitável do mesmo, e, composição farmacêutica
EP1948191B1 (fr) 2005-11-01 2013-01-16 The Regents of the University of Michigan Nouvelles 1,4-benzodiazépine-2,5-diones dotées de propriétés thérapeutiques
US7759338B2 (en) 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
EP2418206A3 (fr) 2006-06-09 2012-06-27 The Regents of the University of Michigan Dérivés de benzodiazépine pour le traitment des troubles auto-immuns
KR101164718B1 (ko) 2007-03-09 2012-07-11 더 리젠츠 오브 더 유니버시티 오브 미시간 신규 화합물 및 이의 표적에 관한 조성물 및 방법
MX2010002732A (es) 2007-09-14 2010-06-02 Univ Michigan Inhibidores de f1f0-atpasa y metodos relacionados.
CN101918375A (zh) 2007-11-06 2010-12-15 密歇根大学董事会 在皮肤病症的治疗中有用的苯并二氮杂*酮化合物
US8497307B2 (en) 2008-09-11 2013-07-30 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
WO2010121164A2 (fr) 2009-04-17 2010-10-21 The Regents Of The University Of Michigan Composés de 1,4-benzodiazépinone et leur utilisation dans le traitement du cancer
EP2470020A4 (fr) 2009-09-18 2013-03-13 Univ Michigan Composés de benzodiazépinone et méthodes de traitement les utilisant
JP5856064B2 (ja) 2009-11-17 2016-02-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 治療特性を有する１，４−ベンゾジアゼピン−２，５−ジオンおよび関連化合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898861A (en) * 1987-03-26 1990-02-06 Hoffmann-La Roche Inc. Method for inhibiting the proliferation of tumor cells
US5776946A (en) * 1995-08-28 1998-07-07 Mcgeer; Patrick L. Peripheral benzodiazepine receptor ligands as antiinflammatory agents
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
FR2779963A1 (fr) * 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
JP5127096B2 (ja) * 1999-04-30 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用
EP1210596A2 (fr) * 1999-06-22 2002-06-05 Mitokor Compositions et procedes d'analyse de conditions infracellulaires et traitement par transert d'energie
US7005274B1 (en) * 1999-09-15 2006-02-28 Migenix Corp. Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
US20020039746A1 (en) * 2000-01-14 2002-04-04 Sjoberg Eric Richard Methods for identifying peripheral benzodiazepine receptor binding agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JONES G.B.: "The non-covalent interaction of pyrrolo(2,1-c)(1,4)benzodiazepine-5,11-diones with DNA", ANTI-CANCER DRUG DESIGN, vol. 5, 1990, pages 249 - 264, XP002966651 *
See also references of EP1423122A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572788B2 (en) 1999-04-30 2009-08-11 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US8415343B2 (en) 1999-04-30 2013-04-09 The Regents Of The University Of Michigan Compositions and methods for inhibiting the proliferation of cells
US8722667B2 (en) 1999-04-30 2014-05-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting the proliferation of cells
US7994313B2 (en) 2005-06-01 2011-08-09 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

Also Published As

Publication number Publication date
NZ531117A (en) 2006-03-31
EP1423122A2 (fr) 2004-06-02
WO2003015703A2 (fr) 2003-02-27
MXPA04001421A (es) 2004-06-03
EP1423122A4 (fr) 2008-12-10
JP2005502652A (ja) 2005-01-27
CA2457405A1 (fr) 2003-02-27
AU2002332560B2 (en) 2006-01-19
NO20041058L (no) 2004-05-14

Similar Documents

Publication Publication Date Title
WO2006029245A3 (fr) Compositions et procedes associes a des nouveaux composes et leurs cibles
WO2005004988A3 (fr) Compositions et procedes de recherche de nouveaux composes et leurs cibles
WO2003015703A3 (fr) Compositions et procedes relatifs a de nouveaux composes de benzodiazepine et leurs cibles
WO2006014526A3 (fr) Compositions et methodes relatives a de nouveaux composes et leurs cibles
WO2006073448A3 (fr) Methodes et compositions de traitement de maladies et de troubles associes a une fonction mitochondriale
WO2008116156A3 (fr) Procédés et compositions pour le traitement de maladies et états associés à la fonction mitochondriale
MX2009009645A (es) Composiciones y metodos relacionados con nuevos compuestos y objetivos de los mismos.
WO2004112719A8 (fr) Composes chimiques
WO2002048147A3 (fr) Composes therapeutiques
EP1507529B8 (fr) Combinaison comprenant valsartane, amlodipine et hydrochlorothiazide
WO2003049702A3 (fr) Ligands de recepteur vanilloide et utilisation de ceux-ci dans des traitements
WO2003095455A3 (fr) Composes therapeutiques
WO2004017920A3 (fr) Nouveaux cannabinoides biphenyle et de type biphenyle
CA2400268A1 (fr) Derives de pyrrolopyrimidinone, procedes d'elaboration et d'utilisation
EP1378240A3 (fr) Compositions pharmaceutiques à base d'arsenic pour le traitement du myelome multiple
WO2004047792A3 (fr) Glucocorticoides liposomaux
WO2007053725A3 (fr) Nouvelles 1,4-benzodiazépine-2,5-diones dotées de propriétés thérapeutiques
CA2359510A1 (fr) Diphenylurees a substituants .omega.-carboxyaryles, inhibitrices de kinase raf
CA2267186A1 (fr) Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique
CA2499330A1 (fr) Nouvelles quinazolinones spiro-condensees et utilisation associee en tant qu'inhibiteurs de phosphodiesterase
WO2007050587A3 (fr) Compositions therapeutiques et procedes
WO2000012504A3 (fr) Dihydro-[1,2,3]triazolo-[4,5-d]pyrimidine-7-one
WO2003005960A3 (fr) Nouveaux cannabinoides bicycliques et tricycliques
WO2006044362A3 (fr) Antagonistes du recepteur 1 de n-sulfonylpiperidine cannabinoide
WO2004105737A3 (fr) Compositions pharmaceutiques et procedes pour inhiber les adherences fibreuses au moyen de differents agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2457405

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 531117

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/001421

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003520664

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002332560

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002794914

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002794914

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 531117

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002332560

Country of ref document: AU